Ascendis Pharma AS (MEX:ASNDN) Piotroski F-Score: 6 (As of Jun. 25, 2026) — 100% Above Median


MEX:ASNDN Ascendis Pharma AS MEX:ASNDN
37 GF Score
Price MXN3,851.44
! 1 Warning Sign
View Full Analysis

What is Ascendis Pharma AS Piotroski F-Score?

Ascendis Pharma AS MEX:ASNDN 37 Piotroski F-Score is 6 as of Jun. 25, 2026, which is 100% above its 10-year median of 3.00. GuruFocus rates MEX:ASNDN with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 1,342 Biotechnology companies, Ascendis Pharma AS ranks better than 92.03% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Ascendis Pharma AS has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Ascendis Pharma AS's Piotroski F-Score or its related term are showing as below:

MEX:ASNDN' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 6
Current: 6

During the past 13 years, the highest Piotroski F-Score of Ascendis Pharma AS was 6. The lowest was 1. And the median was 3.

Ascendis Pharma AS  (MEX:ASNDN) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Ascendis Pharma AS Piotroski F-Score Related Terms


Ascendis Pharma AS Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Piotroski F-Score Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 5.00 4.00 5.00 5.00

Ascendis Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 5.00 5.00 6.00

MEX:ASNDN vs SMMT, BBIO, JAZZ: Piotroski F-Score Comparison

For the Biotechnology subindustry, Ascendis Pharma AS's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma AS Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Piotroski F-Score falls into.


MEX:ASNDN
37GF Score
Ascendis Pharma AS MEX:ASNDN
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -843.839 + -1313.139 + -707.62 + 13119.863 = MXN10,255 Mil.
Cash Flow from Operations was -159.429 + 46.356 + 1547.52 + -160.96 = MXN1,273 Mil.
Revenue was 3432.366 + 4599.7 + 5218.28 + 5140.904 = MXN18,391 Mil.
Gross Profit was 2749.411 + 4118.402 + 4720.74 + 4775.768 = MXN16,364 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(23475.796 + 23626.672 + 24862.635 + 27463.331 + 41762.462) / 5 = MXN28238.1792 Mil.
Total Assets at the begining of this year (Mar25) was MXN23,476 Mil.
Long-Term Debt & Capital Lease Obligation was MXN8,049 Mil.
Total Current Assets was MXN23,397 Mil.
Total Current Liabilities was MXN23,490 Mil.
Net Income was -2157 + -2167.856 + -840.103 + -2092.841 = MXN-7,258 Mil.

Revenue was 709.889 + 1263.872 + 3798.052 + 2232.797 = MXN8,005 Mil.
Gross Profit was 483.797 + 1019.088 + 3491.812 + 1845.374 = MXN6,840 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(14476.697 + 14953.819 + 23903.347 + 25758.318 + 23475.796) / 5 = MXN20513.5954 Mil.
Total Assets at the begining of last year (Mar24) was MXN14,477 Mil.
Long-Term Debt & Capital Lease Obligation was MXN7,903 Mil.
Total Current Assets was MXN20,381 Mil.
Total Current Liabilities was MXN19,585 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Ascendis Pharma AS's current Net Income (TTM) was 10,255. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Ascendis Pharma AS's current Cash Flow from Operations (TTM) was 1,273. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=10255.265/23475.796
=0.43684419

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-7257.8/14476.697
=-0.50134364

Ascendis Pharma AS's return on assets of this year was 0.43684419. Ascendis Pharma AS's return on assets of last year was -0.50134364. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Ascendis Pharma AS's current Net Income (TTM) was 10,255. Ascendis Pharma AS's current Cash Flow from Operations (TTM) was 1,273. ==> 1,273 <= 10,255 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=8049.172/28238.1792
=0.28504572

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=7902.66/20513.5954
=0.38524012

Ascendis Pharma AS's gearing of this year was 0.28504572. Ascendis Pharma AS's gearing of last year was 0.38524012. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=23397.48/23489.687
=0.99607458

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=20380.503/19584.757
=1.04063088

Ascendis Pharma AS's current ratio of this year was 0.99607458. Ascendis Pharma AS's current ratio of last year was 1.04063088. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Ascendis Pharma AS's number of shares in issue this year was 0. Ascendis Pharma AS's number of shares in issue last year was 60.019. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=16364.321/18391.25
=0.8897884

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=6840.071/8004.61
=0.85451646

Ascendis Pharma AS's gross margin of this year was 0.8897884. Ascendis Pharma AS's gross margin of last year was 0.85451646. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=18391.25/23475.796
=0.78341327

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=8004.61/14476.697
=0.55293069

Ascendis Pharma AS's asset turnover of this year was 0.78341327. Ascendis Pharma AS's asset turnover of last year was 0.55293069. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+1+0+1+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Ascendis Pharma AS has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Ascendis Pharma AS (MEX:ASNDN) has a Piotroski F-Score of 6 as of Jun. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Ascendis Pharma AS and its competitors. This is 100% above median its historical median of 3.00. Over the past decade, Ascendis Pharma AS's Piotroski F-Score has ranged from 1.00 to 6.00. According to the industry distribution chart, Ascendis Pharma AS ranks #107 out of 1342 companies in the Biotechnology industry, placing it in the top 8%.
Is Ascendis Pharma AS's Piotroski F-Score too high?
Ascendis Pharma AS's current Piotroski F-Score of 6 is 100% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 6.00. The Biotechnology industry median Piotroski F-Score is 3.00. Ascendis Pharma AS's value of 6 is 100% above this industry median. Based on the distribution chart, Ascendis Pharma AS ranks #107 out of 1342 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Piotroski F-Score compare to SMMT and BBIO?
According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #107 out of 1342 companies for Piotroski F-Score. This places Ascendis Pharma AS in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Ascendis Pharma AS's value of 6 is 100% above this benchmark. Historically, Ascendis Pharma AS's own Piotroski F-Score has ranged from 1.00 to 6.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, Ascendis Pharma AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascendis Pharma AS's current Piotroski F-Score of 6 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Ascendis Pharma AS and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascendis Pharma AS's current Piotroski F-Score is 6, which is 100% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (MEX:ASNDN) has a current Piotroski F-Score of 6. The current Piotroski F-Score is 6, which is 100% above median its 10-year median of 3.00 and 100% above the Biotechnology industry median of 3.00. Ascendis Pharma AS's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Ascendis Pharma AS (MEX:ASNDN), the current Piotroski F-Score is 6 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Other Exchanges ASND:USA
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score

Get the complete analysis for MEX:ASNDN

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,851.44
Price